Details of the Drug Reposition

General Information of This Drug (ID: DMA2B5Y)

Drug Name	DS-3032 DMA2B5Y

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 1	[1]
Haematological malignancy	DISCDP7W	2B33.Y	Phase 1	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01877382) A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)